Table 1.
Disease activity at all visits (A) and change (Δ) in disease activity compared with initial visit (B)
| A. | All | PGA<33 mm | PGA≥33 mm |
| Disease activity: median (IQR) | n=528 | n=243 | n=285 |
| SLEDAI | 4 (2 to 6) | 2 (0 to 4) | 6 (4 to 8) |
| BILAG | 3 (1 to 9) | 1 (1 to 2) | 9 (8 to 10) |
| SSPGA | 33.7 (16.6 to 50.4) | 13.9 (7.1 to 22.3) | 49.5 (38.7 to 55.9) |
| LFA-REAL | 39.1 (18 to 60.9) | 16.7 (8.8 to 27.5) | 58.5 (47.7 to 72.2) |
| B. | All | Improving (SRI-4) | Not improving (SRI-4) |
| Change in disease activity: median (IQR) | n=478 | n=229 | n=249 |
| ΔSLEDAI | −2 (−4 to 0) | −4 (−6 to –4) | 0 (−2 to 1) |
| ΔBILAG | −7 (−8 to 0) | −8 (−8 to –7) | 0 (−6 to 1) |
| ΔSSPGA | −23.1 (−39.4 to −6.1) | −39.1 (−46.9 to −27.2) | −8.8 (−19.4 to 1.9) |
| ΔLFA-REAL | −30.5 (−54.6 to −10.1) | −53 (−66.8 to –36.3) | −14.1 (−26.3 to 0.1) |
BILAG, British Isles Lupus Assessment Group Index; LFA-REAL, Lupus Foundation of America-Rapid Evaluation of Activity in Lupus; SLEDAI, SLE Disease Activity Index; SRI, SLE Responder Index; SSPGA, SELENA SLEDAI Physician’s Global Assessment.